Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007494555> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2007494555 endingPage "53" @default.
- W2007494555 startingPage "53" @default.
- W2007494555 abstract "Because the current therapy in polycythemia vera (PV) and essential thrombocythemia (ET) is aimed at lowering the risk of thrombosis, the risk classification system in these disorders is shaped according to thrombotic risk. Patients with either PV or ET can be stratified in a “high-risk” or “low-risk” category according to their age and previous history of thrombosis. Whether novel risk factors such as leukocytosis and JAK2 mutation may be included in the prognostic stratification requires confirmation in prospective future clinical studies. The identification and appropriate management of cardiovascular risk factors and the promotion of a healthy lifestyle in chronic myeloproliferative neoplasms (MPN), as in the general population, should be considered a cornerstone of vascular prevention. Blood hyperviscosity in PV is a major cause of vascular disturbances which severely impact on morbidity and mortality. An aggressive target of hematocrit lower than 45% in males and 42% in females has been advised by the European LeukemiaNet (ELN) group, although no convincing evidence of this recommendation is currently available. The efficacy and safety of low-dose aspirin (100 mg daily) in PV has been assessed in the European Collaboration on Low-dose Aspirin in Polycythemia (ECLAP) double-blind, placebo-controlled, randomized clinical trial. Translating evidence from the positive results of ECLAP to ET may be questionable. The most commonly used front-line therapy drugs for the treatment of high-risk PV and ET patients include hydroxyurea and alpha-interferon at any age while anagrelide is recommended as second line-therapy in resistant and intolerant ET patients. Busulphan is a front-line therapy in the elderly. By definition, children with ET are a population with low vascular risk unless a major thrombotic or hemorrhagic event has occurred. ELN recommends to prescribe cytoreductive drugs in children as a last resort. No results of clinical trials with JAK-2 inhibitor drugs in PV and ET are so far available." @default.
- W2007494555 created "2016-06-24" @default.
- W2007494555 creator A5089318042 @default.
- W2007494555 date "2007-09-01" @default.
- W2007494555 modified "2023-09-25" @default.
- W2007494555 title "200 INVITED What is known about HPV natural history? Current trends and variation in incidence, mortality and relation to screening programmes in Europe" @default.
- W2007494555 doi "https://doi.org/10.1016/s1359-6349(07)70314-2" @default.
- W2007494555 hasPublicationYear "2007" @default.
- W2007494555 type Work @default.
- W2007494555 sameAs 2007494555 @default.
- W2007494555 citedByCount "0" @default.
- W2007494555 crossrefType "journal-article" @default.
- W2007494555 hasAuthorship W2007494555A5089318042 @default.
- W2007494555 hasConcept C120665830 @default.
- W2007494555 hasConcept C121332964 @default.
- W2007494555 hasConcept C126322002 @default.
- W2007494555 hasConcept C163276114 @default.
- W2007494555 hasConcept C168563851 @default.
- W2007494555 hasConcept C177713679 @default.
- W2007494555 hasConcept C187212893 @default.
- W2007494555 hasConcept C2777628954 @default.
- W2007494555 hasConcept C2778837598 @default.
- W2007494555 hasConcept C2779788118 @default.
- W2007494555 hasConcept C2780829020 @default.
- W2007494555 hasConcept C2781057849 @default.
- W2007494555 hasConcept C2908647359 @default.
- W2007494555 hasConcept C535046627 @default.
- W2007494555 hasConcept C61511704 @default.
- W2007494555 hasConcept C71924100 @default.
- W2007494555 hasConcept C89560881 @default.
- W2007494555 hasConcept C99454951 @default.
- W2007494555 hasConceptScore W2007494555C120665830 @default.
- W2007494555 hasConceptScore W2007494555C121332964 @default.
- W2007494555 hasConceptScore W2007494555C126322002 @default.
- W2007494555 hasConceptScore W2007494555C163276114 @default.
- W2007494555 hasConceptScore W2007494555C168563851 @default.
- W2007494555 hasConceptScore W2007494555C177713679 @default.
- W2007494555 hasConceptScore W2007494555C187212893 @default.
- W2007494555 hasConceptScore W2007494555C2777628954 @default.
- W2007494555 hasConceptScore W2007494555C2778837598 @default.
- W2007494555 hasConceptScore W2007494555C2779788118 @default.
- W2007494555 hasConceptScore W2007494555C2780829020 @default.
- W2007494555 hasConceptScore W2007494555C2781057849 @default.
- W2007494555 hasConceptScore W2007494555C2908647359 @default.
- W2007494555 hasConceptScore W2007494555C535046627 @default.
- W2007494555 hasConceptScore W2007494555C61511704 @default.
- W2007494555 hasConceptScore W2007494555C71924100 @default.
- W2007494555 hasConceptScore W2007494555C89560881 @default.
- W2007494555 hasConceptScore W2007494555C99454951 @default.
- W2007494555 hasIssue "4" @default.
- W2007494555 hasLocation W20074945551 @default.
- W2007494555 hasOpenAccess W2007494555 @default.
- W2007494555 hasPrimaryLocation W20074945551 @default.
- W2007494555 hasRelatedWork W1979131669 @default.
- W2007494555 hasRelatedWork W2007651804 @default.
- W2007494555 hasRelatedWork W2027790755 @default.
- W2007494555 hasRelatedWork W2039687934 @default.
- W2007494555 hasRelatedWork W2059649875 @default.
- W2007494555 hasRelatedWork W2082301773 @default.
- W2007494555 hasRelatedWork W2490143083 @default.
- W2007494555 hasRelatedWork W2603252551 @default.
- W2007494555 hasRelatedWork W3187057186 @default.
- W2007494555 hasRelatedWork W3140408888 @default.
- W2007494555 hasVolume "5" @default.
- W2007494555 isParatext "false" @default.
- W2007494555 isRetracted "false" @default.
- W2007494555 magId "2007494555" @default.
- W2007494555 workType "article" @default.